NOT FOR DISTRIBUTION
Header cover image

Market Cap

€1.4b

Last Updated

2021/05/10 00:45 UTC

Data Sources

Company Financials +

Executive Summary

Drägerwerk AG & Co. KGaA operates as a medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. More Details


Snowflake Analysis

Flawless balance sheet with outstanding track record.


Similar Companies

Share Price & News

How has Drägerwerk KGaA's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: Insufficient data to determine DRW8D's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine DRW8D's volatility change over the past year.


Market Performance


7 Day Return

0%

DRW8D

1.7%

GB Medical Equipment

2.1%

GB Market


1 Year Return

1.0%

DRW8D

2.7%

GB Medical Equipment

26.3%

GB Market

Return vs Industry: DRW8D underperformed the UK Medical Equipment industry which returned 2.7% over the past year.

Return vs Market: DRW8D underperformed the UK Market which returned 26.3% over the past year.


Shareholder returns

DRW8DIndustryMarket
7 Day0%1.7%2.1%
30 Day0%12.0%3.5%
90 Dayn/a5.5%8.8%
1 Year1.2%1.0%4.6%2.7%31.9%26.3%
3 Year18.8%18.2%25.0%17.8%12.9%-0.1%
5 Year14.5%12.9%47.7%35.5%51.5%22.8%

Long-Term Price Volatility Vs. Market

How volatile is Drägerwerk KGaA's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Drägerwerk KGaA undervalued compared to its fair value and its price relative to the market?

7.33x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: DRW8D (€61.6) is trading above our estimate of fair value (€60.64)

Significantly Below Fair Value: DRW8D is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: DRW8D is good value based on its PE Ratio (7.3x) compared to the GB Medical Equipment industry average (49.5x).

PE vs Market: DRW8D is good value based on its PE Ratio (7.3x) compared to the UK market (26.4x).


Price to Earnings Growth Ratio

PEG Ratio: DRW8D's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: DRW8D is good value based on its PB Ratio (1.4x) compared to the GB Medical Equipment industry average (3.8x).


Future Growth

How is Drägerwerk KGaA forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-18.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DRW8D's earnings are forecast to decline over the next 3 years (-18.8% per year).

Earnings vs Market: DRW8D's earnings are forecast to decline over the next 3 years (-18.8% per year).

High Growth Earnings: DRW8D's earnings are forecast to decline over the next 3 years.

Revenue vs Market: DRW8D's revenue (0.6% per year) is forecast to grow slower than the UK market (5.3% per year).

High Growth Revenue: DRW8D's revenue (0.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DRW8D's Return on Equity is forecast to be low in 3 years time (8.6%).


Past Performance

How has Drägerwerk KGaA performed over the past 5 years?

34.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DRW8D has high quality earnings.

Growing Profit Margin: DRW8D's current net profit margins (7.8%) are higher than last year (1%).


Past Earnings Growth Analysis

Earnings Trend: DRW8D's earnings have grown significantly by 34.7% per year over the past 5 years.

Accelerating Growth: DRW8D's earnings growth over the past year (868.7%) exceeds its 5-year average (34.7% per year).

Earnings vs Industry: DRW8D earnings growth over the past year (868.7%) exceeded the Medical Equipment industry 13.8%.


Return on Equity

High ROE: DRW8D's Return on Equity (29.3%) is considered high.


Financial Health

How is Drägerwerk KGaA's financial position?


Financial Position Analysis

Short Term Liabilities: DRW8D's short term assets (€2.0B) exceed its short term liabilities (€948.0M).

Long Term Liabilities: DRW8D's short term assets (€2.0B) exceed its long term liabilities (€1.1B).


Debt to Equity History and Analysis

Debt Level: DRW8D's debt to equity ratio (14.7%) is considered satisfactory.

Reducing Debt: DRW8D's debt to equity ratio has reduced from 36.5% to 14.7% over the past 5 years.

Debt Coverage: DRW8D's debt is well covered by operating cash flow (286.8%).

Interest Coverage: DRW8D's interest payments on its debt are well covered by EBIT (17.4x coverage).


Balance Sheet


Dividend

What is Drägerwerk KGaA current dividend yield, its reliability and sustainability?

0.25%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: DRW8D's dividend (0.25%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.35%).

High Dividend: DRW8D's dividend (0.25%) is low compared to the top 25% of dividend payers in the UK market (4.03%).


Stability and Growth of Payments

Stable Dividend: DRW8D is not paying a notable dividend for the UK market, therefore no need to check if payments are stable.

Growing Dividend: DRW8D is not paying a notable dividend for the UK market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: DRW8D is not paying a notable dividend for the UK market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DRW8D's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.9yrs

Average management tenure


CEO

Stefan Dräger (57 yo)

15.83yrs

Tenure

€3,178,148

Compensation

Mr. Stefan A. Dräger, Dipl.-Ing. B.A., has been the Chief Executive Officer and Chairman of the Executive Board at Drägerwerk Verwaltungs AG, a General Partner of Drägerwerk AG & Co. KGaA (formerly known a...


CEO Compensation Analysis

Compensation vs Market: Stefan's total compensation ($USD3.86M) is above average for companies of similar size in the UK market ($USD1.36M).

Compensation vs Earnings: Stefan's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: DRW8D's management team is seasoned and experienced (5.9 years average tenure).


Board Members

Experienced Board: DRW8D's board of directors are considered experienced (9.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.3%.


Top Shareholders

Company Information

Drägerwerk AG & Co. KGaA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Drägerwerk AG & Co. KGaA
  • Ticker: DRW8D
  • Exchange: BATS-CHIXE
  • Founded: 1889
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €1.406b
  • Shares outstanding: 18.76m
  • Website: https://www.draeger.com

Number of Employees


Location

  • Drägerwerk AG & Co. KGaA
  • Moislinger Allee 53-55
  • Lübeck
  • Schleswig-Holstein
  • 23558
  • Germany

Listings


Biography

Drägerwerk AG & Co. KGaA operates as a medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, a...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/10 00:45
End of Day Share Price2021/03/02 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.